{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:53:23Z","timestamp":1794135203788,"version":"4.8.0"},"reference-count":36,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Purpose: To analyze post-marketing cases of retinal vasculitis after intravitreal pegcetacoplan. Methods: The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee as well as an expert panel performed a retrospective review of cases of retinal vasculitis reported to the ASRS. Clinical and imaging characteristics were reviewed for evidence of retinal vasculitis and analyzed. Results: Fourteen eyes of 13 patients were confirmed to have retinal vasculitis by review of imaging studies. All cases occurred after the first pegcetacoplan injection. Occlusive retinal vasculopathy was confirmed in 11 eyes (79%). Patients presented a median of 10.5 days (range, 8-23 days) after pegcetacoplan injection. All eyes had anterior chamber inflammation, and 12 eyes (86%) had vitritis. Vasculopathy involved retinal veins (100%) more than arteries (73%), and 12 eyes (86%) had retinal hemorrhages. The median visual acuity (VA) was 20\/60 (range, 20\/30-5\/200) at baseline, 20\/300 (range, 20\/100-no light perception [NLP]) at vasculitis presentation, and 20\/200 (range 20\/70-NLP) at the last follow-up. Eight eyes (57%) had more than a 3-line decrease in VA, and 6 eyes (43%) had more than a 6-line decrease in VA from baseline to the final follow-up, including 2 eyes that were enucleated. Six eyes (43%) developed signs of anterior segment neovascularization. Conclusions: There is currently no known etiology for vasculitis in this series. Optimum treatment strategies remain unknown. Infectious etiologies should be considered, and corticosteroid treatments may hasten resolution of inflammatory findings. Continued treatment of affected patients with pegcetacoplan should be avoided.<\/jats:p>","DOI":"10.1177\/24741264231220224","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T02:23:15Z","timestamp":1703211795000},"page":"9-20","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":72,"title":["Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-8098","authenticated-orcid":false,"given":"Andre J.","family":"Witkin","sequence":"first","affiliation":[{"name":"Tufts Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Duke University, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet L.","family":"Davis","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy E.","family":"Kim","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"bibr1-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072618"},{"key":"bibr2-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01520-9"},{"issue":"3","key":"bibr3-24741264231220224","first-page":"509","volume-title":"Am J Ophthalmol","volume":"140","author":"Jabs DA","year":"2005"},{"key":"bibr4-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.09.020"},{"key":"bibr5-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"bibr6-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420930863"},{"key":"bibr7-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"bibr8-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.08.002"},{"key":"bibr9-24741264231220224","unstructured":"Apellis Pharmaceuticals, Inc. Apellis provides update on review of rare safety events with SYFOVRE\n                      \u00ae\n                      (pegcetacoplan injection) for geographic atrophy. July 29, 2023. Accessed November, 2023. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-provides-update-review-rare-safety-events-syfovrer"},{"key":"bibr10-24741264231220224","unstructured":"Apellis Pharmaceuticals, Inc. Apellis provides updates on injection kits and rare safety events with SYFOVRE\n                      \u00ae\n                      (pegcetacoplan injection). August 22, 2023. Accessed November, 2023. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-provides-updates-injection-kits-and-rare-safety-events"},{"key":"bibr11-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/943409"},{"key":"bibr12-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"bibr13-24741264231220224","unstructured":"The United States Food and Drug Administration. Highlights of prescribing information, Beovu\u00ae (brolucizumab-dbll) injection, for intravitreal injection. Published October 2019. Accessed November 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761125s000lbl.pdf"},{"key":"bibr14-24741264231220224","unstructured":"US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. 2021. Accessed November, 2023. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard"},{"key":"bibr15-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.04.006"},{"key":"bibr16-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.138479"},{"key":"bibr17-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181baf691"},{"key":"bibr18-24741264231220224","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20190503-05"},{"key":"bibr19-24741264231220224","unstructured":"US Food and Drug Administration. Summary review. Center for Drug Evaluation and Research. Published September 25, 2019. Accessed November, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761125Orig1s000SumR.pdf"},{"key":"bibr20-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15124"},{"key":"bibr21-24741264231220224","unstructured":"US Food and Drug Administration. Approval package. Center for Drug Evaluation and Research. Published April 15, 2017. Accessed November, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/125156Orig1s114.pdf"},{"key":"bibr22-24741264231220224","unstructured":"US Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s). Center for Drug Evaluation and Research. Published March 30, 2012. Accessed November, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125418Orig1s000ClinPharmR.pdf"},{"key":"bibr23-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.11.001"},{"key":"bibr24-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.11.042"},{"key":"bibr25-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.01.030"},{"key":"bibr26-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4657"},{"key":"bibr27-24741264231220224","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203200"},{"key":"bibr28-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15790"},{"key":"bibr29-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000001069"},{"key":"bibr30-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1634216"},{"key":"bibr31-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2010.18"},{"key":"bibr32-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00929-6"},{"key":"bibr33-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000601"},{"key":"bibr34-24741264231220224","doi-asserted-by":"publisher","DOI":"10.1177\/2474126418806832"},{"key":"bibr35-24741264231220224","unstructured":"US Food and Drug Administration. Integrated review. Center for Drug Evaluation and Research. Published April, 2020. Accessed November, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215014Orig1s000IntegratedR.pdf"},{"key":"bibr36-24741264231220224","unstructured":"Apellis Pharmaceuticals, Inc. Apellis announces preliminary U.S. net revenues of approximately $74 million for SYFOVRE\n                      \u00ae\n                      (pegcetacoplan injection) in the third quarter of 2023. October 5, 2023. Accessed November, 2023. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-announces-preliminary-us-net-revenues-approximately-74"}],"updated-by":[{"DOI":"10.1177\/24741264241238212","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000}}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264231220224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264231220224","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264231220224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:25:47Z","timestamp":1790695547000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264231220224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1177\/24741264231220224"],"URL":"https:\/\/doi.org\/10.1177\/24741264231220224","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}